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Adverse events following vaccination
Database heterogeneitya b s t r a c t
The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public–pri-
vate collaboration aiming to develop and test a system for rapid vaccine benefit-risk monitoring using
existing European healthcare databases. Incidence rate (IR) estimates of vaccination-associated adverse
events that are needed to model vaccination risks can be calculated from existing healthcare databases
when vaccination (exposure) data are available. We assessed different methods to derive IRs in risk peri-
ods following vaccination when exposure data are missing in one database, using estimated IRs and IRRs
from other databases for febrile seizures, fever and persistent crying. IRs were estimated for children aged
0–5 years in outcome-specific risk and non-risk periods following the first dose of acellular pertussis (aP)
vaccination in four primary care databases and one hospital database. We compared derived and
observed IRs in each database using three methods: 1) multiplication of non-risk period IR for database
i by IR ratio (IRR) obtained from meta-analysis of IRRs estimated using the self-controlled case-series
method, from databases other than i; 2) same method as 1, but multiplying with background IR; and
3) meta-analyses of observed IRs from databases other than i. IRs for febrile seizures were lower in pri-
mary care databases than the hospital database. The derived IR for febrile seizures using data from pri-
mary care databases was lower than that observed in the hospital database, and using data from the
hospital database gave a higher derived IR than that observed in the primary care database. For fever
and persistent crying the opposite was observed. We demonstrated that missing IRs for a post-





B48 C. Dodd et al. / Vaccine 38 (2020) B47–B55can have an impact on potential bias. We recommend IRs are derived using data from similar database
types (hospital or primary care) with caution as even this can give heterogeneous results.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction data from the SSI database, which is a hospital database, in sensi-The Accelerated Development of VAccine beNefit-risk Collabo-
ration in Europe (ADVANCE) is a public–private collaboration aim-
ing to develop and test a system for rapid benefit-risk (B/R)
monitoring of vaccines using existing healthcare databases in Eur-
ope (see Appendix for consortium members). A series of proof of
concept (POC) studies were designed to assess the processes and
system proposed for generating the required data to generate evi-
dence on coverage, risks and benefits of vaccines as well as benefit-
risk analyses.
Modelling is one method that is widely used to analyse vaccine
benefit-risk, to understand the impacts of diseases, interventions,
and environmental exposures deterministically or in simulated
populations [1]. Valid estimates of incidence rates (IRs) for
vaccine-preventable disease and adverse events following immu-
nisation, and vaccination coverage are needed to model the
benefit-risk of vaccination [2]. These parameters are typically
obtained in a mix-and-match manner from the literature or by
using data from available healthcare databases [3,4]. When using
healthcare databases, their heterogeneity and potentially impor-
tant missing information on vaccinations need to be taken into
consideration [5].
The first vaccines developed against Bordetella pertussis con-
tained whole killed organisms [6]. Due to the reactogenicity of this
vaccine, Between 2004 and 2015 several countries switched from
whole-cell pertussis (wP) to acellular pertussis (aP) vaccines for
infants and children due to the reactogenicity of the wP vaccine
[7]. In the ADVANCE POC studies the benefits and risks of wP and
aP vaccines in children were compared as an example. For this,
IRs of known benefits and adverse events in outcome-specific risk
periods following each dose of wP and aP vaccine were required.
Since we used existing healthcare databases that collected data
for purposes other than for research, we were faced with the prob-
lem of comparing the effects of exposure which occurred in dis-
tinct time periods, often with missing exposure data for the
period before the switch from wP to aP. To compare the B/R for
the wP and aP vaccines, we attempted to estimate IRs for various
outcomes following wP vaccination in some databases that were
established too recently to contain wP exposure data. In this paper
we compared different methods for deriving IRs in the risk period
following vaccination. To test these methods we limited the anal-
ysis to aP exposure, assuming that the aP exposure data were miss-
ing, which allowed us to compare the observed and derived IRs. In
order to understand the impact of event and database features on
the estimates derived using each method, we conducted a post-hoc
simulation study.
2. Methods
2.1. Data sources and population
This study was conducted with data generated for the
ADVANCE proof of concept study that included seven population-
based healthcare databases from Denmark, Spain, UK and Italy
(Table 1) [8,9]. Two databases were excluded in this methods
study: AUH because it is a subset of the national SSI database in
Denmark, and PEDIANET from Italy, in which vaccination data
was linked only for the 2006 and 2007 birth cohorts. We excludedtivity analyses to study the impact of hospital data on the results.
The study population comprised all children aged < 6 years reg-
istered in any of the participating databases during the study per-
iod, who had received at least the first dose of aP vaccine. For the
calculation of background rates, children were followed from start
of the study period (1 January 1990), one month after their date of
birth (to allow for pre-vaccination person time and to avoid pre-
term related or birth-induced increase in IR), or date of valid data
in the database, whichever occurred the latest. For the calculation
of baseline rates and incidence rate ratios, children were followed
from 31 days before their first dose of aP vaccine. All children were
followed until the end of study period (31 December 2015), until
they receipt of their pertussis booster dose, transferring out of
the database, death, reaching age 6 years, or end of data availability
in the database, whichever occurred first. Children with missing
date of birth or sex were excluded.
Data from each participating database was extracted locally and
transformed into a common data model, comprising vaccination,
event, and population files [10].
2.2. Outcomes
To test the methodology we selected three outcomes from the
risk study that have different patterns of care: febrile convulsions,
fever, and persistent crying. Febrile convulsions are rare and are
usually considered to be serious clinical events requiring presenta-
tion to the emergency room. Fever is common but does not often
require hospitalisation. Persistent crying is non-specific and often
lacks a specific diagnosis code even in primary care. Definitions,
codes and methods for data extraction and harmonisation can be
found in other papers in this supplement [9,10].
2.3. Definition of exposure
Data on aP vaccination were obtained from the healthcare data-
bases [9]. Although our study was driven by the need to estimate
IRs during the wP risk period, we limited our methodological study
to aP risk period since the IRs could be estimated in all participat-
ing databases; therefore we could compare the IRs derived using
different methods with the estimated IRs.
Outcome-specific risk windows were defined as day 0 to 3 for
febrile convulsions and fever and day 0 to 1 for persistent crying,
with day 0 being the day of vaccination. Baseline periods were
defined as 31–8 days before dose one and the interval from the last
day of the risk window to 31 days after the dose. The week prior to
vaccination was excluded from the baseline period to avoid the
‘healthy vaccinee effect’, i.e. vaccine avoidance by subjects experi-
encing an illness (Fig. 1) [11]. The pertussis vaccination schedules
were 3, 5 and 12months, 2, 4 and 11 months and 2, 3 and 4 months
for Denmark, Spain and UK, respectively.
2.4. Statistical methods
IRs (per 1000 person years) were calculated by age in months
and in the aP vaccination risk and non-risk period for each out-
come. We conducted self-controlled case series (SCCS) analyses
for each of the outcomes to obtain IRRs, comparing risk to non-
risk periods for the first dose of aP vaccination [12]. The study pop-
Table 1
Databases providing data for the ADVANCE POC safety study [9].
Country Database Geographic
coverage
















































GP medical records 2003–2014 2004 2.0
million
152,784 Yes (READ) Yes (READ)
United Kingdom THIN National
sample
GP medical records 1996–2013 2004 8.3
million
576,151 Yes (READ) Yes (READ)
AUH = Aarhus University Hospital, SSI = Statens Serum Institut, BIFAP = Base de datos para la Investigación Famacoepidemiológica en Atención Primaria, SIDIAP = Information
System for Research in Primary Care, RCGP RSC = Royal College of General Practitioners Research and Surveillance Centre, THIN = The Health Information Network,
GP = General Practitioner, ICD = International Classification of Diseases.
Fig. 1. Schematic representation of the timeline of a typical observation period for
dose 1.
Fig. 2. Approach for calculating risk window specific incidence rates in databases wh
C. Dodd et al. / Vaccine 38 (2020) B47–B55 B49ulation for each outcome-specific SCCS analysis included children
who experienced the event at least once during their follow-up.
For each database i and event, a leave-one-out (L-O-O) random
effects IRR was estimated using ameta-analysis of the IRRs from all
databases other than database i, independent of the type of data
source [13]. I-square measures of heterogeneity were calculated
for each L-O-O meta-analysis. The result is referred to as L-O-
O_IRR _ma. IRs in the risk period following vaccination were
derived using three methods (Box). In the first method, we multi-
plied the baseline IR calculated in non-risk periods around aP vac-
cination in database i by the L-O-O_IRR_ma that excluded database
i (IR_bl) (Fig. 2). In the second method, we multiplied the back-en wP exposure is missing or under the assumption of missing aP exposure [8].
B50 C. Dodd et al. / Vaccine 38 (2020) B47–B55ground IR that was calculated in the month of age at the recom-
mended first dose by the L-O-O_IRR_ma that excluded database i
(IR-bg). In the third method, we derived a pooled risk period IR
using a meta-analysis of the IRs for the observed risk period for
all databases other than i (IR_ma). We then assessed the agreement
between observed and derived risk period IRs.2.5. Statistical simulation study
In a post-hoc analysis, we conducted a simulation study to
assess the impact of database type (hospitalization vs. general
practitioner), risk period length, baseline incidence of the event,
and true incidence rate ratio in the risk vs. baseline period for each
of the incidence rate derivation methods. Full methods and results
of this simulation study are provided in supplementary material
(Supplementary File 1).Fig. 3. Background incidence of events of interest per 1000 person years by age in
months and database (NB: the y-axes are not the same scale).3. Results
3.1. Test case, acellular pertussis vaccines
The study population comprised 2.6 million children
aged < 6 years who had received at least one dose of aP-
containing vaccine. The database-specific sample sizes varied from
152,784 (RCGP RSC) to 980,843 (SSI) (Table 1). Over 400,000 chil-
dren experienced at least one of the three events of interest during
the study period.
The overall background IR (per 1000 person-years) in this pae-
diatric population for febrile convulsion ranged between 3 (BIFAP)
to 11 (SSI; hospitalization). The age-stratified IRs peaked between
1 and 2 years of age in all databases (Fig. 3). For fever, the overall IR
(per 1000 person-years) varied between the databases from 8 (SSI)
to 184 (BIFAP). The age-stratified IRs for fever were high up to
18 months of age in most of the databases (Fig. 3).
The overall IRs (per 1,000 person-years) of persistent crying
ranged from 2 (THIN) to 22 (BIFAP). The age-stratified IRs peaked
in the first months of life and then declined rapidly (Fig. 3). No data
for persistent crying were available in the SIDIAP and SSI databases
since there are no specific ICD-9 or ICD-10 codes for this event. The
event was identified using BIFAP-specific-ICPC or ICD-9 codes as
well as free-text in the BIFAP database.
IRRs for adverse events following vaccination which compared
the IRs in risk periods after aP vaccination with those at baseline,
as estimated via SCCS analyses, varied between databases. For feb-
rile convulsions, no significant association after dose one of aP vac-
cine was seen in the BIFAP and RCGP RSC databases, while the risk
was significantly lower in the SSI and THIN databases. L-O-O
IRR_ma estimates were closer to 1 than those estimated in the
SCCS in all databases. Statistically significant protective effects
observed in the SSI and THIN databases were no longer present
in the L-O-O_IRR_ma estimates. When the estimates from the SSI
database were excluded, the L-O-O_IRR_ma estimates increased
slightly closer 1 due to removal of the significantly protective IRR
in the SSI database (Table 2).
IRRs for fever showed a significant protective effect in the BIFAP
and SIDIAP databases whereas the risk was increased in the SSI
database and no association was observed in the THIN and RCGP
RSC databases. Again, L-O-O meta-analysis removed much of the
heterogeneity in these results. All L-O-O_IRR_ma estimates had
confidence intervals including one (Table 2).
Persistent crying was significantly elevated in all databases that
provided data for this event. L-O-O_IRR_ma results were consistent
across databases and remained significantly greater than one.
Because SSI did not contribute persistent crying cases, removal of
SSI had no impact on L-O-O_IRR_ma estimates (Table 2).The IR_bl and IR_bg methods performed similarly for febrile
convulsions, tending to underestimate observed risk period IRs.
In the primary care databases, with the exception of RCGP RSC,
the derived IR_ma tended to be higher than the observed IR,
because of the impact of the elevated incidence from the hospital
database, SSI. For the SSI database, the observed risk period IR
was higher than the derived IR_ma as this was based on the risk
period IRs of the primary care databases (Fig. 4a). In analyses
excluding SSI, IR_bl and IR_bg performed similarly and were in
agreement with the observed risk period IR except in the RCGP
RSC database (Fig. 4b). The IR_ma method produced higher esti-
mates with wider confidence intervals than IR_bl and IR_bg in all
scenarios (Fig. 4a, 4b).
For fever the IR_bl and IR_bg methods gave similar results, i.e.,
derived IR estimates that were generally lower than the observed
estimates. The derived IR_ma estimates were similar across data-
bases. In the BIFAP database where the background IR for fever
was highest, the IR_ma underestimated the observed IR for the risk
period while in the SSI database, where the background rate of
fever was the lowest, the IR_ma overestimated the IR for the risk
period compared with the observed IR. (Figs. 3, 4a). In analyses
Table 2
Self-controlled case series (SCCS) and leave-one-out (L-O-O) incidence rate ratios (IRRs) following dose one of acellular pertussis vaccine.
Event Database SCCS IRR
(95% CI)
L-O-O IRR
(95% CI) | I2
L-O-O IRR without SSI
(95% CI) | I2
Febrile convulsions SSI 0.24 (0.18; 0.31) 0.88 (0.32; 2.39) | 69.66 NA
BIFAP 2.23 (0.77; 6.47) 0.46 (0.18; 1.18) | 79.23 0.63 (0.20; 1.98) | 67.65
SIDIAP 0.40 (0.13; 1.27) 0.72 (0.20; 2.57) | 89.44 1.12 (0.33; 3.77) | 72.75
RCGP RSC 1.93 (0.66; 5.65) 0.48 (0.18; 1.32) | 82.01 0.67 (0.19; 2.30) | 72.81
THIN 0.31 (0.10; 0.98) 0.76 (0.21; 2.74) | 89.53 1.23 (0.43; 3.50) | 63.66
Fever SSI 1.33 (1.21; 1.47) 0.83 (0.62; 1.11) | 97.93 NA
BIFAP 0.72 (0.67; 0.78) 0.96 (0.65; 1.43) | 98.73 0.87 (0.56; 1.33) | 98.56
SIDIAP 0.58 (0.54; 0.62) 1.02 (0.78; 1.33) | 97.12 0.93 (0.72; 1.21) | 95.86
RCGP RSC 1.12 (0.96; 1.30) 0.87 (0.61; 1.22) | 98.76 0.75 (0.54; 1.04) | 98.35
THIN 1.01 (0.94; 1.08) 0.89 (0.60; 1.31) | 98.64 0.77 (0.57; 1.04) | 96.83
Persistent crying SSI NA 2.38 (1.55; 3.64) | 93.01 NA
BIFAP 1.60 (1.34; 1.91) 2.95 (2.56; 3.39) | 0 2.95 (2.56; 3.39) | 0
SIDIAP NA 2.38 (1.55; 3.64) | 93.01 2.38 (1.55; 3.64) | 93.01
RCGP RSC 2.83 (2.18; 3.66) 2.19 (1.18; 4.06) | 96.16 2.19 (1.18; 4.06) | 96.16
THIN 3.00 (2.54; 3.54) 2.11 (1.20; 3.68) | 92.14 2.11 (1.20; 3.68) | 92.14
BIFAP = Base de datos para la Investigación Famacoepidemiológica en Atención Primaria, RCGP RSC = Royal College of General Practitioners Research and Surveillance Centre,
SIDIAP = Information System for Research in Primary Care, SSI = Statens Serum Institut, THIN = The Health Information Network, SCCS = Self Controlled Case Series. L-O-
O = Leave-one-out.
Fig. 4. Comparison of results from the three methods for calculating incidence rates (IRs) for febrile convulsions, fever and persistent crying following aP vaccination (A) in all
databases and (B) in primary care databases (excluding SSI). BIFAP = Base de datos para la Investigación Famacoepidemiológica en Atención Primaria, RCGP RSC = Royal
College of General Practitioners Research and Surveillance Centre, SIDIAP = Information System for Research in Primary Care, SSI = Statens Serum Institut, THIN = The Health
Information Network, aPE = acellular pertussis vaccine.
C. Dodd et al. / Vaccine 38 (2020) B47–B55 B51
B52 C. Dodd et al. / Vaccine 38 (2020) B47–B55excluding SSI, IR_bl and IR_bg significantly underestimated the
observed risk period IRs in all databases except for the BIFAP and
SIDIAP databases, while the IRs from IR_ma were similar across
databases and produced an underestimation of observed risk per-
iod IR in BIFAP (Fig. 4b).
For persistent crying, the results from the IR_bl and IR_bg
approaches were similar. In the UK databases, the IRs derived by
both methods were slightly lower than the observed risk period
IRs, but not statistically significantly lower, whereas the IRs
derived by both IR_bl and IR_bg were higher than those observed
for the BIFAP database. The risk period IRs derived by the IR_ma
method were similar across databases but they were underesti-
mated compared with the observed risk period IRs in the BIFAP
and RCGP RSC databases, and overestimated compared with the
observed risk period IRs in the THIN database (Fig. 4a). Since no
data for persistent crying events were available from the SSI data-
base, its removal had no impact on the estimated IRs (Fig. 4b).3.2. Statistical simulation study
In simulated data for different scenarios of multidatabase stud-
ies, the IR_bl method consistently performed better than other
methods as measured by 95% confidence interval coverage. The
simulation results confirmed the finding that IR_bl and IR_bg
methods perform similarly when the true IRR is small. The IR_bg
method slightly outperformed the IR_bl method for rare events
with a small IRR. Increasing risk period length and increasing IRR
negatively impacted the performance of the IR_bg method. The
IR_bl method performed consistently well for common events in
both GP and hospital databases. For rare events, performance of
the IR_bl method improved with increasing IRR and increasing risk
period length. The IR_ma method performed poorly except in the
case of rare events in hospital databases when the majority of data-
bases were hospital databases, and for rare events in GP databases
when the majority of the databases in the study were also GP data-
bases. Full results of the statistical simulation can be found in sup-
plementary material.4. Discussion
The results from this study demonstrate that it is possible to
obtain estimates for event-specific IRs occurring during risk win-
dows after vaccination in a certain database using incidence rate
ratios and incidence rates from other data sources, even if the data
on the type of vaccination (for the IR_bl method) or the occurrence
of vaccination (for the IR_bg and IR_ma methods) are not available
in that database. The results also demonstrate that use of IR esti-
mates from other data sources may not always be valid, since the
type of data source (e.g. primary care setting versus hospital set-
ting) has a major impact, which differs by type of event and the
care pattern for that event. Febrile convulsions are acute and can
lead to emergency room visits and, therefore, primarily appear in
hospital records [14,15]. Since the SSI database contains only
hospital-derived data, this might explain why the background,
baseline and risk period incidence rates are higher in the SSI data-
base than in the other databases which contain primary care-
derived data (SIDIAP, BIFAP, THIN, and RCGP RSC). The observed
IRs for febrile convulsions and their peak at around 15–16 months
of age, especially in the SSI database, are consistent with those in
the literature that reports a peak incidence at around 18 months
old [16,17]. The derived estimates for febrile convulsions IRs were
in much better agreement with observed risk period IRs when the
SSI hospital-based database was removed because of the difference
in background incidence between primary care and hospital
databases.The post-vaccination IRs for fever derived using baseline or
background rates produced estimates that were lower than the
observed IRs in the risk window. Fever had a very low background
incidence in the SSI database because it is a symptom and is unli-
kely be recorded as a hospital discharge diagnosis. The IRs derived
using meta-analysis also tended to be lower than the observed risk
period IRs except in the SSI database where the observed risk per-
iod IR was low. Removal of SSI did not improve the agreement
between the derived IRs and observed risk period IRs due to its
small contribution and therefore minimal changes to the L-O-O
estimates.
Persistent crying is a non-specific condition that is not easy to
record using medical coding systems and only the BIFAP database
had specific codes for this event. Agreement was good for the
methods in all databases, except BIFAP where the derived IRs using
baseline and background rates were over-estimates compared
with the observed risk period IRs, due to the higher baseline and
background rates of persistent crying in BIFAP. The usefulness of
the IR_ma estimates for the BIFAP, RCGP RSC and THIN databases
is uncertain as they are derived from the meta-analysis of data
from the other two databases while for the SIDIAP and SSI data-
bases the IR_ma is the only estimate available due to the absence
of persistent crying events in these databases.
In general, IR_ma estimates produced wider CIs due to our use
of a random-effectsmeta-analysis and therefore, the 95% CIs for the
IR_ma estimates were more likely to contain the observed IR. The
L-O-O_IRR_ma estimates were similar across databases for each
event, irrespective of which database was left out, suggesting that
any differences in the resulting IR_bl or IR_bg estimates were due
to difference in underlying baseline or background rates.
The aim of this study was to assess methods to fill gaps in infor-
mation in one database using estimates from other databases. We
demonstrated that this is possible, but that how data for each
event are captured should be taken into consideration, as this
may have a greater impact on the absolute IRs than on the IRRs.
If an event, such as fever or persistent crying, is not captured in a
database, we recommend that the pooled IRs (IR_ma) from data-
bases which were able to capture the event of interest in similar
settings are used. For example, the incidence of febrile convulsions
was lower in the primary care databases than in the hospital data-
base, but the IR_ma method produced derived IRs that were more
in line with those observed in the hospital database. This method
may be preferable if observed IRs in primary care databases are
assumed to be underestimated.
Although the type of event may have an important impact on
the performance of methods for derivation, we demonstrated that
the IR_bl and IR_bg methods provided very similar results for the
events we used, which means that the approach using the back-
ground IRs (which does not require vaccine exposure time) can
be used. This may be because the risk periods represent a very
small period in comparison with the total follow-up period, and
the risk increase was small during the risk period. These methods
may be preferable if background and baseline IRs are assumed to
be accurate, and the IR_bg method may be preferable if the risk
period is short or cannot be observed due to missing exposure data.
From simulations, we were able to determine that database mix
(GP vs. hospital) has little impact on derived estimates other than
those obtained using the IR_ma method. When the risk period is
short and the IRR is small, the IR_bl and the IR_bgmethods perform
similarly. The IR_ma method has little utility except for rare events
when the majority of the databases in the sample are of the same
type.
This study has limitations. First, calculation of IRs using the
IR_bl method requires availability of a proxy exposure around
which a baseline period can be constructed; this will often be
unavailable. The IR_bg method relies on baseline rates which will
C. Dodd et al. / Vaccine 38 (2020) B47–B55 B53vary widely from database to database. The use of absolute mea-
sures which rely on baseline rates has been criticized in the context
of reporting of the number needed to treat [19]. As illustrated by I2
values, estimates obtained from the included databases were
highly heterogeneous, limiting the utility of the IR_ma method.
Additionally, it has been argued in themeta-analysis literature, rel-
ative measures of effect should be used in meta-analyses rather
than absolute measures of effect such as an incidence rate [18].
While these limitations are relevant, the approaches presented
here may still represent an improvement over the selection of
available parameter estimates from the literature that is widely
practiced in modelling studies.
5. Conclusions
Although we were able to compare derived and observed IRs for
aP exposure, we did not have the estimates of the true incidence of
each event in the post-wP vaccination risk period in all databases.
We cannot draw general conclusions regarding which method pro-
vides the best estimates of the true incidence, but we can conclude
that, in the test case presented here, characterized by short risk
windows and small increases in IRRs, the IR_bl and IR_bg methods
provide similar estimates. Additionally, the IR_ma method may
provide derived IRs that are closer to the observed IRs when these
latter come from a similar type of database. However, it is impor-
tant to note that this method is sensitive to heterogeneity in base-
line incidence in each of the database as it uses absolute measures
of incidence [18,20]. Heterogeneity among data sources may have
been increased by differences in vaccination schedules and coding
systems as well as database type. (See Box 1)Box 1 Methods used to derive incidence rates in risk period fol-
lowing vaccination.
(1) Derived from baseline IR (IR_bl):
The baseline IR in database i was multiplied by the L-O-
O_IRR_ma calculated excluding database i. Confidence inter-
vals (CIs) were obtained by calculating the standard error of
the log IR_bl as follows:
The standard error of the sum of the log IR and the log L-O-
O_IRR_ma was calculated as:ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi







(2) Derived from background IR (IR_bg):
The background IR of each outcome in the month of age
when the first dose was recommended in the country of data-
base, i, was multiplied by the L-O-O_IRR_ma calculated
excluding database i. CIs were obtained by calculating the
standard error of the log IR_bg as in equations (1) and (2).
(3) Derived via meta-analysis of risk period IRs (IR_ma):
The log-transformed risk period IRs of all databases except
database i were meta-analysed, providing IR_ma. CIs were
obtained using the DerSimonian and Laird method for random
effects meta-analysis [13].Based upon simulations, we recommend that the IR_bl method
be used when an estimate of baseline incidence is available. If an
estimate of baseline incidence is not available, the IR_bg method
may be used if the IRR is low. The IR_ma method should not be
used if another method can be applied. If applied, it should only
be used for rare events only when the majority of databases inthe sample are of the same type as that with missing data. We
demonstrated that the type of events and databases have a large
impact and it is important to distinguish if the events are diag-
nosed in primary care, hospital or both, and perform stratified
analyses for the type of events the databases capture. It is impor-
tant to have a clear understanding of the external and internal val-
idation of the databases as well as the heterogeneity of the studied
databases and those used for deriving the parameters before pro-
ceeding to parameter derivation. We conclude that derived IRs
for events following vaccination in the absence of specific vaccine
exposure data in a specific database is possible if the background
IRs can be calculated and IRRs are available from a similar type
of database.
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